Biotech | September 26, 2021
U.S. FDA completes inspection of Biocon Biologics, Malaysia with six observations
The company does not expect the outcome of this inspection to impact its plans
The company does not expect the outcome of this inspection to impact its plans
_256_384.jpg)
Terumo’s first product was the domestically produced, safe, high-quality thermometer. The company has since supported the healthcare ecosystem worldwide
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
The net proceeds from the issue will be utilised towards the purchase of machinery, modernising existing units and expansion of its R&D facilities
Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
Amptron’s R &D is based out of the US and this will enable Max to obtain US and other global certifications. Max will retain the right to market, sell and distribute the products in India.
The investment is part of the group's digital health initiatives, to foster affordable access to world-class technology and an innovation-led healthcare ecosystem in India
Union Minister addresses the 13th CII Global MedTech Summit on the sunrise medical devices sector in India
Key trends indicate that AI-based solutions, cloud-based healthcare solutions and digital transformations will be the key in the years to come.
The Stasis connected care monitoring system includes - a bedside monitor that monitors 6 vital signs, a tablet that enables intuitive monitoring, and the Stasis app that allows for remote monitoring across devices
Subscribe To Our Newsletter & Stay Updated
